+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemoglobinopathies - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309474
The global market for Hemoglobinopathies is estimated at US$814.2 Million in 2023 and is projected to reach US$1.3 Billion by 2030, growing at a CAGR of 6.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Sickle Cell Disease Indication segment, which is expected to reach US$716.2 Million by 2030 with a CAGR of 5.9%. The Beta Thalassemia Disease Indication segment is also set to grow at 6.4% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $248.8 Million in 2023, and China, forecasted to grow at an impressive 5.8% CAGR to reach $227.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Hemoglobinopathies Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hemoglobinopathies Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Hemoglobinopathies Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Diagnostics, Bio-Rad Laboratories, Inc., Danaher Corporation, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 38 Featured):

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Hemoglobinopathy - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Alpha Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 22: World Hemoglobinopathies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
JAPAN
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Japan 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
CHINA
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: China Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: China 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
EUROPE
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
FRANCE
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: France Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: France 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
GERMANY
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Germany 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Italy 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: UK Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: UK 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 83: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Rest of Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Rest of Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Asia-Pacific Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • Table 95: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Rest of World Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Rest of World 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

Table Information